Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 71.53

+2.4%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob oserin who wrote (2439)	1/30/1999 5:51:00 PM
From: Abuckatatime	Read Replies (1) of 4676

Isis comments on previously published ISIS 5132 data. In a letter to the editor in Feb 99 Nature Medicine, Isis reports that results of a study presented in a previous report (Nature Medicine, June 1996) were partially invalidated as a result of data manipulation by a scientist in the Novartis research department. Following the disclosure of the manipulation in March 1998 Isis and Novartis apparently repeated the experiments necessary to determine the validity of the previously published results. Isis now confirms that "all the in vitro, as well as the in vivo mRNA expression data, is accurate but that the data showing inhibition of tumor growth following administration of the C-raf antisense in tumor xenograft models is not." C-raf antisense displayed anti-tumor activity against a variety of tumor types in xenograft models but the doses necessary to achieve anti-tumor effects were higher than those described in the earlier report "(10-20 mg/kg compared with 0.6 mg/kg)." 1996 abstract- ncbi.nlm.nih.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next